Description
Warfarin is an orally available antithrombotic commonly used for preventing blood clot formation and migration. The S enantiomer of warfarin is somewhat more potent than the R enantiomer. This coumarin inhibits the subunit 1 of the vitamin K epoxide reductase complex (VKORC1), depleting the reduced form of vitamin K (KH2) and inhibiting the formation of coagulation factors II, VII, IX, and X. Warfarin has a relatively slow onset and requires 1 to 2 days to take effect. This compound is highly sensitive to a wide variety of genetic polymorphisms and is metabolized by cytochrome P4502C9; it also interacts with many other medications and foods, requiring diligent activity monitoring.
References
Hall AM, Wilkins MR. Warfarin: a case history in pharmacogenetics. Heart. 2005 May;91(5):563-4. PMID: 15831631.
Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002 Mar;194(3):267-73. PMID: 11893129.
Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. PMID:1564123.
Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985 Nov;76(5):1879-84. PMID: 3932474.
Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science. 1973 Jan 12;179(4069):192-4. PMID: 4682251.
